To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Vol:8 Issue:1 Number:24 ISSN#:2564-2537
DOWNLOAD ESPAÑOL
Meta-Analysis
ACE Report #10252
Ace Report Cover Metabolic Disorders

Larger BMD gains in osteoporosis patients transitioning to denosumab versus other active controls


How to Cite

OrthoEvidence. Larger BMD gains in osteoporosis patients transitioning to denosumab versus other active controls. ACE Report. 2019;8(1):24. Available from: https://myorthoevidence.com/AceReport/Report/10252

Study Type:Meta-analysis/Systematic Review
OE Level Evidence:1
Journal Level of Evidence:N/A

Safety and efficacy of denosumab in osteoporotic patients previously treated with other medications: a systematic review and metaanalysis

Expert Opin Drug Saf. 2018 Apr;17(4):413-428

Contributing Authors:
EI Kenanidis ME Potoupnis E Tsiridis A Fontalis E Prousali

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

6 randomized controlled trials were included in this meta-analysis which aimed to compare increase in bone mineral density measurements between denosumab and other active anti-osteoporosis medications among postmenopausal women with osteoporosis and who had previously been administered anti-osteoporosis therapy. In pooled analyses, percent increase in bone mineral density measured at the total hip...

Ace Report Preview Image
CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE
For Reprints and Permissions, click here

Please Login or Join to leave comments.